{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"USBrandName","name":"Breyanzi"},{"type":"CodeName","name":"JCAR017"},{"type":"Synonym","name":"autologous anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T lymphocytes JCAR017"},{"type":"Synonym","name":"anti-CD19-CAR genetically engineered autologous T lymphocytes JCAR017"},{"type":"Synonym","name":"autologous anti-CD19-EGFRt-4-1BB-zeta-modified CAR CD8+ and CD4+ T lymphocytes JCAR017"},{"type":"CodeName","name":"JCAR 017"},{"type":"Synonym","name":"Liso-cel"}],"definition":{"html":"A preparation of a defined ratio of CD4+ and CD8+ autologous T lymphocytes transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) containing an anti-CD19 single chain variable fragment (scFv) fused to the signaling domain of 4-1BB (CD137), the zeta chain of the TCR/CD3 complex (CD3-zeta), and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, lisocabtagene maraleucel is directed to and induces selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. Devoid of both ligand binding domains and tyrosine kinase activity, the expressed EGFRt both facilitates in vivo detection of the administered, transduced T cells and can promote elimination of those cells through a cetuximab-induced antibody dependent cellular cytotoxicity (ADCC) response. The 4-1BB costimulatory signaling domain enhances both proliferation of T cells and antitumor activity.","text":"A preparation of a defined ratio of CD4+ and CD8+ autologous T lymphocytes transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) containing an anti-CD19 single chain variable fragment (scFv) fused to the signaling domain of 4-1BB (CD137), the zeta chain of the TCR/CD3 complex (CD3-zeta), and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon intravenous administration, lisocabtagene maraleucel is directed to and induces selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. Devoid of both ligand binding domains and tyrosine kinase activity, the expressed EGFRt both facilitates in vivo detection of the administered, transduced T cells and can promote elimination of those cells through a cetuximab-induced antibody dependent cellular cytotoxicity (ADCC) response. The 4-1BB costimulatory signaling domain enhances both proliferation of T cells and antitumor activity."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/lisocabtagenemaraleucel","text":"Lisocabtagene Maraleucel"},"nciConceptId":"C125192","nciConceptName":"Lisocabtagene Maraleucel","termId":778386,"name":"lisocabtagene maraleucel","firstLetter":"l","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"lisocabtagene-maraleucel"}],"links":null}